Amgen (AMGN)
(Delayed Data from NSDQ)
$319.66 USD
+2.18 (0.69%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $319.25 -0.41 (-0.13%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$319.66 USD
+2.18 (0.69%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $319.25 -0.41 (-0.13%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Zacks News
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $206.78, marking a +1.8% move from the previous day.
Esperion (ESPR) to Cut 40% Workforce, Revamp Cost Structure
by Zacks Equity Research
Esperion (ESPR) is set reduce its workforce by 40% and start targeted program savings to reduce its operational expense and deliver consistent growth.
Zacks Value Trader Highlights: AT&T, Verizon, Amgen, Poshmark, and The RealReal
by Zacks Equity Research
Zacks Value Trader Highlights: AT&T, Verizon, Amgen, Poshmark, and The RealReal
How to Find Stocks on Sale in 2021
by Tracey Ryniec
Looking for hidden gems isn't too hard with this simple stock screen.
3 Small Biotech Stocks in Focus on World Arthritis Day
by Indrajit Bandyopadhyay
Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications.
AstraZeneca (AZN) COVID-19 Antibody Meets Goal in TACKLE Study
by Zacks Equity Research
AstraZeneca (AZN) posts positive results from the phase III TACKLE study on the AZD7442 combo for treating mild-to-moderate COVID-19 in the outpatient setting. The study has met its primary endpoint.
Amgen (AMGN) Reports New Data From Lumakras Combo Study
by Zacks Equity Research
Amgen (AMGN) reports new combination data from the phase Ib CodeBreaK 101 study. It also buys a stake in Neumora Therapeutics to advance novel therapies for brain diseases.
Bristol Myers (BMY) UC Candidate Fails in Phase II Study
by Zacks Equity Research
Bristol Myers (BMY) suffers a setback as its phase II study of deucravacitinib for the treatment of moderate to severe ulcerative colitis fails to meet primary and secondary endpoints.
Biohaven (BHVN) Q3 Nurtec Preliminary Sales Top Expectations
by Zacks Equity Research
Biohaven's (BHVN) sole marketable drug, Nurtec ODT reports preliminary sales for the third quarter, which beat expectations.
This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Biotech Stock Roundup: XLRN Up on Takeover Rumor, NVAX, BIIB Offer Updates & More
by Zacks Equity Research
Regulatory and pipeline updates from bigwigs like Biogen (BIIB) and Novavax (NVAX) have been some of the key highlights in the biotech sector during the past week.
AbbVie's (ABBV) Migraine Prevention Drug Qulipta Gets FDA Nod
by Zacks Equity Research
The FDA approves AbbVie's (ABBV) Qulipta (atogepant) for preventive treatment of episodic migraine in adults.
The Zacks Analyst Blog Highlights: Tesla, JPMorgan, Oracle, Amgen and Lam Research
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tesla, JPMorgan, Oracle, Amgen and Lam Research
Top Analyst Reports for Tesla, JPMorgan & Oracle
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), JPMorgan Chase & Co. (JPM), and Oracle Corporation (ORCL).
Biohaven (BHVN) Phase III Multiple System Atrophy Study Fails
by Zacks Equity Research
Biohaven's (BHVN) myeloperoxidase enzyme inhibitor, verdiperstat fails to statistically differentiate from placebo in improving disease progression in patients with multiple system atrophy in a late-stage study.
Amgen (AMGN) Repatha Gets FDA Nod for Expanded Use in Kids
by Zacks Equity Research
FDA approves Amgen's (AMGN) Repatha for pediatric patients, 10 years of age and older, with familial hypercholesterolemia, both heterozygous and homozygous forms.
Onconova (ONTX) KRAS Inhibitor Shows Activity in Lung Cancer
by Zacks Equity Research
Onconova (ONTX) is developing a combination of its rigosertib plus Bristol-Myers' Opdivo for treating cancer with solid tumors. Preliminary data from the phase I/II study demonstrates disease control potential.
Mirati (MRTX) Reports Positive Data From Colorectal Cancer Study
by Zacks Equity Research
Mirati (MRTX) reports positive data from a cohort of the phase I/IIstudy evaluating its KRAS inhibitor adagrasib in patients with KRAS G12C-mutated colorectal cancer.
The Zacks Analyst Blog Highlights: Bank of America, PepsiCo, Wells Fargo, T-Mobile and Amgen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bank of America, PepsiCo, Wells Fargo, T-Mobile and Amgen
Top Analyst Reports for Bank of America, PepsiCo & Wells Fargo
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), PepsiCo, Inc. (PEP), and Wells Fargo & Company (WFC).
Stock Market News for Sep 10, 2021
by Zacks Equity Research
U.S. stock markets closed lower on Thursday as investors await the decision of the U.S. Federal Reserve with regard to the monetary policy.
Merck's (MRK) Keytruda Gets Nod for Expanded Use in China
by Zacks Equity Research
Merck's (MRK) Keytruda gets approval in combination with chemotherapy in the first-line setting for advanced esophageal and GEJ cancer in China based on data from the phase III KEYNOTE-590 study.
Impel (IMPL) Gets FDA Nod for Trudhesa in Migraine Treatment
by Zacks Equity Research
The FDA approves Impel's (IMPL) Trudhesa nasal spray for the acute treatment of migraine with or without aura in adults.
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $225.96 in the latest trading session, marking a +1.17% move from the prior day.
Amgen (AMGN) Down 2.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.